Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

Trial Profile

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Rituximab
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Dec 2015 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021, as reported by ClinicalTrials.gov.
    • 01 Dec 2015 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2021, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top